Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Clearmind Medicine Inc. (CMNDF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.50000.0000 (0.00%)
At close: 12:45PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.5000
Open0.5000
BidN/A x N/A
AskN/A x N/A
Day's Range0.5000 - 0.5000
52 Week Range0.4127 - 0.7300
Volume1,754
Avg. Volume3,231
Market Cap16.444M
Beta (5Y Monthly)1.57
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Clearmind Medicine's VP of Business Development Presented at The Canadian Psychedelics Association Event

    The CPA's Panel for physicians and medical professionals addressed "New Psychedelic Substances" TORONTO, Jan. 13, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (CSE: CMND, FSE: CWY0, OTC Pink: CMNDF) (“Clearmind” or the "Company"), a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and undertreated health problems, today announces that its newly appointed VP Business Development, psychedelic medicine ex

  • GlobeNewswire

    Clearmind Medicine Strengthens Presence in North America with New Senior Appointments

    Mr. Mark Haden appointed to VP Business Development and Mr. Gilad Babchuk as Head of Strategy and CommunicationTORONTO, Jan. 11, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (CSE: CMND, FSE: CWY0, OTC Pink: CMNDF) (“Clearmind” or the "Company"), a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and undertreated health problems, is pleased to announce senior appointments to its management team in North

  • GlobeNewswire

    Clearmind Medicine Establishes Third R&D Partnership With the Hebrew University

    Research will focus on developing novel patentable psychedelics as potential drug candidatesTORONTO, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (CSE: CMND, FSE: CWY0, OTC Pink: CMNDF) (“Clearmind” or the “Company”), a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and undertreated health problems, is pleased to announce it has entered an new agreement to fund further research and developme

Advertisement
Advertisement